OS Therapies shares rise 11.11% intraday after successful pre-Marketing Authorisation Application Meeting with UK MHRA on Phase 2b OST-HER2 trial.
ByAinvest
Tuesday, Jan 13, 2026 3:37 pm ET1min read
OSTX--
OS Therapies surged 11.11% intraday following the announcement of a successful pre-Marketing Authorisation Application Meeting with the UK MHRA regarding its Phase 2b clinical trial of OST-HER2. The meeting, a critical step in regulatory approval processes, signals advancing development of the therapy and bolsters investor confidence in the company’s pipeline. The positive news directly aligns with the stock’s intraday rally, reflecting optimism over potential market access for OST-HER2 in the UK.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet